The FDA on May 10, 2019 approved CYRAMZA® as a single agent for HepatoCellular Carcinoma (HCC) in patients who have an Alpha FetoProtein (AFP) of 400 ng/mL or more, and have been previously treated with NEXAVAR® (Sorafenib). CYRAMZA® is a product of Eli Lilly and Company.
Bottom Ad
Advertisement
Subscribe
